Evidence map›Paper›PMID 35925930›Full record

Observational studyPloS one2022

Thromboembolic events in COVID-19 ambulatory patients: An observational study about incidence, and thromboprophylaxis outcomes.

Rania Hammami, Jihen Jdidi, Olfa Chakroun, Fadhila Issaoui, Nouha Ktata, Hanen Maamri, Mouna Baklouti, Amine Bahloul, Rania Gargouri, Abdennour Nasri and 6 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Rania HammamiCardiology Department, Hedi Chaker Hospital, University of Medicine, Sfax University, Sfax, Tunisia.ORCID 0000-0003-1168-6450
Jihen JdidiEpidemiology Department Hedi Chaker Hospital, University of Medicine, Sfax University, Sfax, Tunisia.
Olfa ChakrounEmergency Department, University Hospital Habib Bourguiba Sfax, University of Medicine, Sfax University, Sfax, Tunisia.ORCID 0000-0002-9224-7080
Fadhila IssaouiEmergency Department, University Hospital Habib Bourguiba Sfax, University of Medicine, Sfax University, Sfax, Tunisia.
Nouha KtataEpidemiology Department Hedi Chaker Hospital, University of Medicine, Sfax University, Sfax, Tunisia.
Hanen MaamriEpidemiology Department Hedi Chaker Hospital, University of Medicine, Sfax University, Sfax, Tunisia.
Mouna BakloutiEpidemiology Department Hedi Chaker Hospital, University of Medicine, Sfax University, Sfax, Tunisia.
Amine BahloulCardiology Department, Hedi Chaker Hospital, University of Medicine, Sfax University, Sfax, Tunisia.
Rania GargouriCardiology Department, Hedi Chaker Hospital, University of Medicine, Sfax University, Sfax, Tunisia.
Abdennour NasriEmergency Department, University Hospital Habib Bourguiba Sfax, University of Medicine, Sfax University, Sfax, Tunisia.
Sameh MsaadPneumology department, Hedi Chaker Hospital, University of Medicine, Sfax University, Sfax, Tunisia.
Samy KammounPneumology department, Hedi Chaker Hospital, University of Medicine, Sfax University, Sfax, Tunisia.
Samir KammounCardiology Department, Hedi Chaker Hospital, University of Medicine, Sfax University, Sfax, Tunisia.
Imen Ben RejabEmergency Departement, Gabes Hospital, Gabes, Tunisia.
Selma CharfeddineCardiology Department, Hedi Chaker Hospital, University of Medicine, Sfax University, Sfax, Tunisia.
Leila AbidCardiology Department, Hedi Chaker Hospital, University of Medicine, Sfax University, Sfax, Tunisia.
Hopital Universitaire Hedi Chaker · TNUniversity of Sfax · TNUniversity of Gabès · TN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThere are no clear data about the incidence and the prophylactic strategies of arterial and venous thromboembolic events (TE) in COVID-19 ambulatory patients. Thus, we conducted this study to analyze thromboembolic complications in this setting and to assess thromboprophylaxis management and outcomes in the real life. PATIENTS AND

methodsThis is an observational study including Covid-19 ambulatory patients. We assessed incidence of venous and arterial TE events as well as thromboprophylaxis outcomes and hemorrhagic complications. We defined high risk thrombo-embolic factor according to the Belgian guidelines which are the only guidelines that described thromboprophylaxis in COVID-19 ambulatory patients.

resultsWe included 2089 patients with a mean age of 43±16 years. The incidence of 30 days venous and arterial TE complications in our cohort was 1%. Venous thromboembolic complications occurred in 0.8% and arterial thromboembolic complications occurred in 0.3%.We noted at least one high-risk TE factor in 18.5% of patients but thromboprophylaxis was prescribed in 22.5% of the cases, LMWH in 18.1%, and Rivaroxaban in 3.7%. Hemorrhagic events occurred in eight patients (0.3%): five patients showed minor hemorrhagic events and three patients showed major ones (0.14%).

conclusionsOur study showed that the incidence of thromboembolic complications is very low in COVID-19 ambulatory patients. Paradoxically, there is an over prescription of thrombo-prophylaxis in this population.

Indexed as

COVID-19Venous ThromboembolismAdultAnticoagulantsHemorrhageHeparin, Low-Molecular-WeightHumansIncidenceMiddle AgedAnticoagulantsHeparin, Low-Molecular-Weight

Identifiers

PMID35925930
PMCPMC9352084
OpenAlexW4289848707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.